Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Statin in Clinical and Preclinical Knee Osteoarthritis-What E vidence Exists for Future Clinical Use?-A Literature Review

Author(s): Md Abu Bakar Siddiq*, Israt Jahan and Johannes J. Rasker

Volume 19, Issue 3, 2023

Published on: 03 November, 2022

Page: [270 - 280] Pages: 11

DOI: 10.2174/1573397118666220930141740

Price: $65

Abstract

Background: Statins are used to lower serum cholesterol. Recent preclinical and clinical research focuses on articular cartilage regeneration aspects of statin. This review summarizes the effects of statins on knee osteoarthritis (OA).

Methods: Published preclinical and clinical literature till November 2021 were searched in PubMed and PubMed Central databases. Articles not written in English, not relevant for the review, and unpublished evidence were excluded. Finally, 27 papers were reviewed and presented in the study.

Results: A total of 27 articles have been included-13 clinical and 14 preclinical studies. Preclinical studies showed statin-induced chondroprotective effects; these included in vitro studies on human or animal-derived degenerated articular cartilage as well as OA animal models. Chondroprotective effects of statins are thought to mediate by inhibiting the Wnt/β-catenin signaling pathway, preventing synovial inflammation, and inhibiting catabolic-stress-induced aging of cartilage. Preclinical study outcomes were based on biochemical, macroscopic, and microscopic (histology) assessments and seemed promising in cartilage regeneration. In the 13 clinical studies, the effect of statins on human OA is inconclusive: some showing improvement of OA symptoms, and others depict signs of aggravation and radiological progression. No randomized controlled trial (RCT) has tested the efficacy of intra-articular statins in clinical knee OA, and it seems feasible to avoid oral statinassociated severe adverse effects.

Conclusion: There are no arguments to recommend oral statins in clinical OA-knee. An RCT testing the efficacy of oral statins in patients with OA knee was never done and still seems justified, as well as a prospective phase-II clinical trial for intra-articular statins in different types of OA.

Keywords: Articular, cartilage, knee, osteoarthritis, statin, treatment

« Previous Next »
Graphical Abstract

[1]
Rebalka IA, Cao AW, May LL, Tarnopolsky MA, Hawke TJ. Statin administration activates system xC − in skeletal muscle: A potential mechanism explaining statin-induced muscle pain. Am J Physiol Cell Physiol 2019; 317(5): C894-9.
[http://dx.doi.org/10.1152/ajpcell.00308.2019] [PMID: 31509447]
[2]
Auer J, Sinzinger H, Franklin B, Berent R. Muscle- and skeletal-related side-effects of statins: Tip of the iceberg? Eur J Prev Cardiol 2016; 23(1): 88-110.
[http://dx.doi.org/10.1177/2047487314550804] [PMID: 25230981]
[3]
Buettner C, Rippberger MJ, Smith JK, Leveille SG, Davis RB, Mittleman MA. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012; 125(2): 176-82.
[http://dx.doi.org/10.1016/j.amjmed.2011.08.007] [PMID: 22269621]
[4]
Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: Mechanisms and management. Diabetes Care 2013; 36 (Suppl. 2): S325-30.
[http://dx.doi.org/10.2337/dcS13-2038] [PMID: 23882066]
[5]
Price S. Commonly used drugs prevent cartilage degradation. Nat Rev Rheumatol 2010; 6(10): 554.
[http://dx.doi.org/10.1038/nrrheum.2010.145] [PMID: 20925143]
[6]
Siddiq MAB, Clegg D, Jansen TL, Rasker JJ. Emerging and new treatment options for knee osteoarthritis. Curr Rheumatol Rev 2022; 18(1): 20-32.
[http://dx.doi.org/10.2174/1573397117666211116111738] [PMID: 34784876]
[7]
Mohajer B, Guermazi A, Conaghan PG, et al. Statin use and MRI subchondral bone marrow lesion worsening in generalized osteoarthritis: longitudinal analysis from osteoarthritis initiative data. Eur Radiol 2022; 32(6): 3944-53.
[http://dx.doi.org/10.1007/s00330-021-08471-y] [PMID: 35043291]
[8]
Dinc M, Bilgen MS, Kucukalp A, Bilgen OF. An assessment of the chondroprotective effects of intra-articular application of statin and tetracycline on early-stage experimental osteoarthritis. ISRN Orthop 2012; 2012: 1-9.
[http://dx.doi.org/10.5402/2012/182097] [PMID: 24977073]
[9]
Zhang P, Han F, Li Y, et al. Local delivery of controlled-release simvastatin to improve the biocompatibility of polyethylene terephthalate artificial ligaments for reconstruction of the anterior cruciate ligament. Int J Nanomedicine 2016; 11: 465-78.
[http://dx.doi.org/10.2147/IJN.S95032] [PMID: 26869789]
[10]
Yu SM, Kim SJ. Simvastatin prevents articular chondrocyte dedifferentiation induced by nitric oxide by inhibiting the expression of matrix metalloproteinases 1 and 13. Exp Biol Med (Maywood) 2018; 243(15-16): 1165-72.
[http://dx.doi.org/10.1177/1535370218820650] [PMID: 32459510]
[11]
Baker JF, Walsh PM, Byrne DP, Mulhall KJ. Pravastatin suppresses matrix metalloproteinase expression and activity in human articular chondrocytes stimulated by interleukin-1β. J Orthop Traumatol 2012; 13(3): 119-23.
[http://dx.doi.org/10.1007/s10195-012-0200-4] [PMID: 22684544]
[12]
Izadpanah R, Schächtele DJ, Pfnür AB, et al. The impact of statins on biological characteristics of stem cells provides a novel explanation for their pleotropic beneficial and adverse clinical effects. Am J Physiol Cell Physiol 2015; 309(8): C522-31.
[13]
Valdes AM, Zhang W, Muir K, Maciewicz RA, Doherty S, Doherty M. Use of statins is associated with a lower prevalence of generalised osteoarthritis. Ann Rheum Dis 2014; 73(5): 943-5.
[http://dx.doi.org/10.1136/annrheumdis-2013-204382] [PMID: 24347568]
[14]
Critical Appraisals Skills Programme (CASP). CASP check-lists. Oxford: CASP 2020. Available from: https://casp-uk.net/casp-tools-checklists/ (Accessed April 19, 2021).
[15]
Haj-Mirzaian A, Mohajer B, Guermazi A, et al. Statin use and knee osteoarthritis outcome measures according to the presence of heberden nodes: Results from the osteoarthritis initiative. Radiology 2019; 293(2): 396-404.
[http://dx.doi.org/10.1148/radiol.2019190557] [PMID: 31502936]
[16]
Eymard F, Parsons C, Edwards MH, et al. Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. Joint Bone Spine 2018; 85(5): 609-14.
[http://dx.doi.org/10.1016/j.jbspin.2017.09.014] [PMID: 29037516]
[17]
Clockaerts S, Van Osch GJVM, Bastiaansen-Jenniskens YM, et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012; 71(5): 642-7.
[http://dx.doi.org/10.1136/annrheumdis-2011-200092] [PMID: 21989540]
[18]
Kadam UT, Blagojevic M, Belcher J. Statin use and clinical osteoarthritis in the general population: A longitudinal study. J Gen Intern Med 2013; 28(7): 943-9.
[http://dx.doi.org/10.1007/s11606-013-2382-8] [PMID: 23471638]
[19]
Campion J, Western A. Statins and joint pain. Br J Clin Pharmacol 2008; 66(4): 570-1.
[http://dx.doi.org/10.1111/j.1365-2125.2008.03218.x] [PMID: 18537962]
[20]
Michaëlsson K, Lohmander LS, Turkiewicz A, Wolk A, Nilsson P, Englund M. Association between statin use and consultation or surgery for osteoarthritis of the hip or knee: A pooled analysis of four cohort studies. Osteoarthritis Cartilage 2017; 25(11): 1804-13.
[http://dx.doi.org/10.1016/j.joca.2017.07.013] [PMID: 28756279]
[21]
Riddle DL, Moxley G, Dumenci L. Associations between Statin use and changes in pain, function and structural progression: A longitudinal study of persons with knee osteoarthritis. Ann Rheum Dis 2013; 72(2): 196-203.
[http://dx.doi.org/10.1136/annrheumdis-2012-202159] [PMID: 23172752]
[22]
Cook MJ, Sorial AK, Lunt M, Board TN, O’Neill TW. Effect of timing and duration of statin exposure on risk of hip or knee revision arthroplasty: a population-based cohort study. J Rheumatol 2020; 47(3): 441-8.
[http://dx.doi.org/10.3899/jrheum.180574] [PMID: 30877207]
[23]
Makris UE, Alvarez CA, Mortensen EM, Mansi IA. Association of statin use with increased risk of musculoskeletal conditions: a retrospective cohort study. Drug Saf 2018; 41(10): 939-50.
[http://dx.doi.org/10.1007/s40264-018-0682-y] [PMID: 29797239]
[24]
Veronese N, Koyanagi A, Stubbs B, et al. Statin use and knee osteoarthritis outcomes: a longitudinal cohort study. Arthritis Care Res (Hoboken) 2019; 71(8): 1052-8.
[http://dx.doi.org/10.1002/acr.23735] [PMID: 30144308]
[25]
Horecka A, Hordyjewska A, Blicharski T, et al. Simvastatin effect on calcium and silicon plasma levels in postmenopausal women with osteoarthritis. Biol Trace Elem Res 2016; 171(1): 1-5.
[http://dx.doi.org/10.1007/s12011-016-0635-1] [PMID: 26858096]
[26]
Zhou M, Guo Y, Wang D, et al. The cross-sectional and longitudinal effect of hyperlipidemia on knee osteoarthritis: Results from the Dongfeng-Tongji cohort in China. Sci Rep 2017; 7(1): 9739.
[http://dx.doi.org/10.1038/s41598-017-10158-8] [PMID: 28852192]
[27]
Simopoulou T, Malizos KN, Poultsides L, Tsezou A. Protective effect of atorvastatin in cultured osteoarthritic chondrocytes. J Orthop Res 2010; 28(1): 110-5.
[PMID: 19623662]
[28]
Lazzerini PE, Capecchi PL, Nerucci F, et al. Simvastatin reduces MMP-3 level in interleukin 1 stimulated human chondrocyte culture. Ann Rheum Dis 2004; 63(7): 867-9.
[http://dx.doi.org/10.1136/ard.2003.009746] [PMID: 15194586]
[29]
Bayyurt S, Küçükalp A, Bilgen MS, Bilgen ÖF, Çavusoğlu I, Yalçinkaya U. The chondroprotective effects of intraarticular application of statin in osteoarthritis. Indian J Orthop 2015; 49(6): 665-71.
[http://dx.doi.org/10.4103/0019-5413.168751] [PMID: 26806976]
[30]
Akasaki Y, Matsuda S, Nakayama K, Fukagawa S, Miura H, Iwamoto Y. Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis Cartilage 2009; 17(2): 235-43.
[http://dx.doi.org/10.1016/j.joca.2008.06.012] [PMID: 18672387]
[31]
Tanaka T, Matsushita T, Nishida K, et al. Attenuation of osteoarthritis progression in mice following intra‐articular administration of simvastatin‐conjugated gelatin hydrogel. J Tissue Eng Regen Med 2019; 13(3): 423-32.
[http://dx.doi.org/10.1002/term.2804] [PMID: 30644168]
[32]
Terabe K, Takahashi N, Cobb M, Askew EB, Knudson CB, Knudson W. Simvastatin promotes restoration of chondrocyte morphology and phenotype. Arch Biochem Biophys 2019; 665: 1-11.
[http://dx.doi.org/10.1016/j.abb.2019.01.038] [PMID: 30776329]
[33]
Yu SM, Han Y, Kim SJ. Simvastatin induces differentiation in rabbit articular chondrocytes via Wnt/β-catenin pathway. Eur J Pharmacol 2019; 863: 172672.
[http://dx.doi.org/10.1016/j.ejphar.2019.172672] [PMID: 31542485]
[34]
Pathak NN, Balaganur V, Lingaraju MC, et al. Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: Implication for osteoarthritis therapy. Pharmacol Rep 2015; 67(3): 513-9.
[http://dx.doi.org/10.1016/j.pharep.2014.12.005] [PMID: 25933963]
[35]
Aktas E, Sener E, Gocun PU. Mechanically induced experimental knee osteoarthritis benefits from anti-inflammatory and immunomodulatory properties of simvastatin via inhibition of matrix metalloproteinase-3. J Orthop Traumatol 2011; 12(3): 145-51.
[http://dx.doi.org/10.1007/s10195-011-0154-y] [PMID: 21863259]
[36]
Yudoh K, Karasawa R. Statin prevents chondrocyte aging and degeneration of articular cartilage in osteoarthritis (OA). Aging (Albany NY) 2010; 2(12): 990-8.
[http://dx.doi.org/10.18632/aging.100213] [PMID: 21098883]
[37]
Min JL, Meulenbelt I, Riyazi N, et al. Association of the frizzled-related protein gene with symptomatic osteoarthritis at multiple sites. Arthritis Rheum 2005; 52(4): 1077-80.
[http://dx.doi.org/10.1002/art.20993] [PMID: 15818669]
[38]
Baudart P, Louati K, Marcelli C, Berenbaum F, Sellam J. Association between osteoarthritis and dyslipidaemia: A systematic literature review and meta-analysis. RMD Open 2017; 3(2): e000442.
[http://dx.doi.org/10.1136/rmdopen-2017-000442] [PMID: 29435358]
[39]
Xiong J, Long J, Chen X, Li Y, Song H. Dyslipidemia Might Be Associated with an Increased Risk of Osteoarthritis. BioMed Res Int 2020; 2020: 3105248.
[http://dx.doi.org/10.1155/2020/3105248] [PMID: 32149100]
[40]
Thaper A, Zhang W, Wright G, Doherty M. Relationship between Heberden’s nodes and underlying radiographic changes of osteoarthritis. Ann Rheum Dis 2005; 64(8): 1214-6.
[http://dx.doi.org/10.1136/ard.2004.031450] [PMID: 15677702]
[41]
Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008; 337: a2286.
[http://dx.doi.org/10.1136/bmj.a2286] [PMID: 18988647]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy